Overview

Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA^® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

11/20/20	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , Nov. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 19, 2020 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 140,500 shares
11/05/20	Coherus BioSciences Reports Third Quarter 2020 Financial Results – Third Quarter UDENYCA® Net Sales of $113 . 6 Million – – Net Income of $27 . 9 Million – – Non-GAAP Net Income of $39 . 7 Million – REDWOOD CITY, Calif. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and
10/22/20	Coherus BioSciences to Report Third Quarter Financial Results on November 5th REDWOOD CITY, Calif. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020 . Starting at 4:30 p.m.
10/16/20	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , Oct. 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 15, 2020 , the compensation committee of the Company’s board of directors granted a newly hired Executive Vice President an option to

View All